JUL 30, 2019 11:39 AM PDT

Treating Drug-Resistant Acute Lymphoblastic Leukemia

WRITTEN BY: Nouran Amin

New therapeutics may have helped improve survival rates for acute lymphoblastic leukemia patients but some patients still remain unresponsive to existing treatment regimens. To make matters worse, drug resistance is not the only concern--the risk of drug-related toxicities among patients has pushed researchers to seek safer and effective therapeutics.

Now, scientists from Case Western Reserve University School of Medicine have developed a novel combination treatment regimen that enhances immune system function and improve the ability to kill leukemia’s that do not respond to standard protocol treatments. Findings were published in Cancer Immunology Research and describes the use of mouse models to illustrate how an antibody attaches to a specific protein on the cell surface of acute lymphoblastic leukemia cells and creates a bridge by attaching to a natural killer that quickly works to eradicate the cancer cell.

"If we started to treat mice with the antibody early during disease development, leukemia was almost eradicated by this treatment method; however, if treatment was administered late when the tumor had grown and established its own microenvironment, the antibody alone was less effective," said Parameswaran, who is also a member of the Case Comprehensive Cancer Center and a St. Baldrick's Scholar. "There was a clear negative effect of the tumor microenvironment on natural killer cell killing capacity," Parameswaran said. "So, we added a TGF-beta receptor inhibitor to our antibody treatment regimen."

Watch this video below to learn more on acute lymphoblastic leukemia:

The treatment uses BAFF-R antibody, which attaches to the BAFF-R protein on cancer cells. The antibody is currently being used to treat autoimmune diseases and rheumatoid arthritis in two clinical trial studies.

"We looked at BAFF-R expression in a small group of 16 patients and all of them expressed this receptor. It's promising as a therapeutic avenue for late-stage disease" Parameswaran said. Data from larger patient sets will help us draw a definitive conclusion."

Source: Case Western University

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
Treating Malaria: Molecular Understanding of Drug Interactions
Crystallization is a process central to drug development that despite centuries of facilitating a particular method, chemists are still learning how to gra...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 08, 2020
Drug Discovery & Development
FEB 08, 2020
Drug Targets Brain-Eating Amoebas
Brain-eating amoebas lead to high rates of mortality as a result of encephalitis. In fact, more than 95% of people who develop the infection will die. Unfo...
FEB 24, 2020
Drug Discovery & Development
FEB 24, 2020
Leukemic Drugs May Target Lung Cancer
Two approved therapeutics for treating leukemia are currently being investigated for treatment-resistant lung cancer.  The findings were based on a li...
MAR 23, 2020
Drug Discovery & Development
MAR 23, 2020
Is Fast-Tracking Vaccines for Coronavirus Really Such a Good Idea?
Donald Trump has called on researchers to “slash red tape like nobody has even done it before” to accelerate the development of vaccines for th...
Loading Comments...